What is Arcus Biosciences's cumulative cost basis?

Arcus Biosciences (RCUS) reported cumulative cost basis of $877M in Q1 2026.

How has Arcus Biosciences's cumulative cost basis changed year-over-year?

Arcus Biosciences's cumulative cost basis decreased by 12.7% year-over-year, from $1.01B to $877M.

What is the long-term trend for Arcus Biosciences's cumulative cost basis?

Over 3 years (2022 to 2025), Arcus Biosciences's cumulative cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $1.15B to $1.01B.

Arcus Biosciences RCUS Cumulative Cost Basis

Cumulative Cost Basis at other companies

Regeneron PharmaceuticalsREGN

——

AbbVieABBV

——

IncyteINCY

——

ImmunityBio, Inc.IBRX

——

BillionToOne, Inc. BLLN

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's cumulative cost basis?: Arcus Biosciences (RCUS) reported cumulative cost basis of $877M in Q1 2026.
How has Arcus Biosciences's cumulative cost basis changed year-over-year?: Arcus Biosciences's cumulative cost basis decreased by 12.7% year-over-year, from $1.01B to $877M.
What is the long-term trend for Arcus Biosciences's cumulative cost basis?: Over 3 years (2022 to 2025), Arcus Biosciences's cumulative cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $1.15B to $1.01B.